UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000630
Receipt number R000000748
Scientific Title Voriconazole versus Micafungin for empirical antifungal therapy in patients with neutropenia and persistent fever
Date of disclosure of the study information 2008/12/31
Last modified on 2012/03/24 10:15:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Voriconazole versus Micafungin for empirical antifungal therapy in patients with neutropenia and persistent fever

Acronym

Voriconazole versus Micafungin in patients with FN

Scientific Title

Voriconazole versus Micafungin for empirical antifungal therapy in patients with neutropenia and persistent fever

Scientific Title:Acronym

Voriconazole versus Micafungin in patients with FN

Region

Japan


Condition

Condition

febril neutropenia

Classification by specialty

Hematology and clinical oncology Infectious disease

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

A comparison between Voriconazole and Micafungin for empirical antifungal therapy in patients with neutropenia and persistent fever

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

defervesce and survival rate after two and four weeks from starting treatment

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Micafugin150mg iv once a day

Interventions/Control_2

Voriconazole 6mg/kg iv twice a day on day1,followed by 4mg/kg iv twice daily

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)fever with tempreture above 38.0 degree. 2)neutropenia(<500cells/uL)for at least 4days. 3)injectable antibacterials for at least 4days.

Key exclusion criteria

1)AST/ALT/total bilirubin>5 times the upper limit of normal(at each institution).2)Karnofsky score<30%.3)Documented invasive fungal infection before starting treatment.4)History of treatment by voriconazole or mycafungin.5)History of allergy or hypersensitivity to voriconazole or mycafungin.6)Not eligible for the study in the opinion of investigators

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoji Ishida

Organization

Iwate Medical unversity

Division name

Hematology

Zip code


Address

19-1 utimaru morioka Iwate Janpan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Iwate Medical unversity

Division name

Hematology

Zip code


Address


TEL

019-651-5111

Homepage URL


Email



Sponsor or person

Institute

Division of hematology,Iwate medical unversity

Institute

Department

Personal name



Funding Source

Organization

Division of hematology,Iwate medical unversity

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 12 Month 31 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2007 Year 01 Month 31 Day

Date of IRB


Anticipated trial start date

2007 Year 02 Month 01 Day

Last follow-up date

2008 Year 12 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2011 Year 12 Month 01 Day


Other

Other related information



Management information

Registered date

2007 Year 03 Month 06 Day

Last modified on

2012 Year 03 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000748


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name